Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 54: 1418-1420, 2008; 10.1373/clinchem.2008.111542
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Dam, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Dam, R. M.
(Clinical Chemistry. 2008;54:1418-1420.)
© 2008 American Association for Clinical Chemistry, Inc.


Editorials

Coffee Consumption and Coronary Heart Disease: Paradoxical Effects on Biological Risk Factors versus Disease Incidence

Rob M. van Dam

Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, and Department of Nutrition, Harvard School of Public Health, Boston, MA

Address correspondence to the author at: Department of Nutrition, Bldg. 2, Harvard School of Public Health, Boston, MA 02115, E-mail rvandam{at}hsph.harvard.edu

Coffee consumption has been shown to have adverse effects on various biological markers of coronary heart disease (CHD) risk, including serum cholesterol (1), blood pressure (2), insulin resistance (3), and plasma homocysteine (4). In contrast, higher coffee consumption has not been associated with a higher risk of CHD in prospective cohort studies (5)(6)(7). What could be the explanation for this "coffee paradox"? First, the acute effects of coffee consumption can be different from the effects of long-term habitual consumption. Second, the physiological effects of coffee can depend on the type of coffee consumed and are not necessarily the same as for caffeine in isolation. Third, coffee consumption may have beneficial effects on other biological pathways implicated in the development of CHD that could compensate for any adverse effects. Fourth, risk markers may not causally affect the development of CHD, or their effects may be too modest for any increase caused by coffee consumption to translate into a substantial increase in disease risk. Research supporting these explanations are discussed, with particular focus on the association between coffee consumption and homocysteine concentrations reported by Ulvik et al. in this issue of Clinical Chemistry (8).

In caffeine-naive individuals, caffeine intake leads to a marked reduction in insulin sensitivity (3) and marked increases in postload glucose concentrations (9), epinephrine concentrations (10), and blood pressure (10). Within a week of initiating caffeine intake, however, an individual experiences an attenuation of coffee’s effects on epinephrine release and blood pressure (10). For blood pressure, only a partial tolerance develops, and a modest increase remains after several weeks (2). Given that caffeine’s stimulation of epinephrine release appears to contribute to insulin resistance (3), it is plausible that the effect of caffeine on glucose metabolism would also attenuate after continued caffeine intake. There is limited evidence that the increase in insulin concentration caused by high caffeine intake remains after 1–4 weeks (11)(12). In contrast, the results of prospective cohort studies suggest that long-term caffeinated coffee consumption is not substantially associated with a risk of hypertension (13) and may lower the risk of type 2 diabetes (14). Thus, partial tolerance to the effects of caffeine can develop, but longer-term trials on the effects of coffee on biological risk factors are needed to bridge the gap in the data between short-term trials and cohort studies.

With regard to the type of coffee, the effect of coffee consumption on serum cholesterol depends on the brewing method. In randomized trials, high consumption of boiled coffee led to a substantial increase in LDL cholesterol, whereas high consumption of paper-filtered coffee had little effect (1). The diterpene cafestol has been identified as the cholesterol-raising component of coffee (15). For paper-filtered coffee, the filter prevents substantial amounts of cafestol from getting into the coffee, whereas cafestol remains in boiled, French press, and Turkish/Greek coffee (15). Coffee is a complex mixture of hundreds of plant compounds that may interact in their physiological effects. Most research on coffee components has focused on caffeine, and it is tempting to directly extrapolate the physiological effects that have been found for caffeine in isolation to those of coffee. However, the effects of coffee on exercise performance (16), epinephrine concentrations (16), blood pressure(2), and hyperglycemia (9) all appear to be weaker than the effects of the same amount of caffeine used in isolation. Recently, the acute effects of caffeine, caffeinated coffee, and decaffeinated coffee on responses to an oral glucose tolerance test were evaluated (9). Compared with placebo, caffeine increased postload glucose concentrations, caffeinated coffee showed a nonsignificant increase, and decaffeinated coffee produced a significant decrease in glucose concentrations. Similarly, trials of caffeinated coffee tended to show weaker effects on blood pressure than trials of caffeine in isolation (2), and the coffee phenol chlorogenic acid may reduce blood pressure (17). In line with these results, the consumption of other caffeine-containing drinks, but not caffeinated coffee, was associated with a higher risk of developing hypertension (13). These findings suggest that components in coffee other than caffeine have physiological effects that are opposite to those of caffeine. For example, quinides may counteract the adenosine receptor antagonism caused by caffeine (18).

Ulvik et al. report an association between higher coffee consumption and higher plasma homocysteine concentrations in a large population-based cross-sectional study (8). This finding is consistent with results from previous observational studies (19) and randomized trials (4)(20)(21)(22). Both caffeine (20) and chlorogenic acid (21) have been shown to contribute to the homocysteine-raising effect of coffee. Caffeine (1,3,7-trimethylxanthine) has been postulated to possibly inhibit the vitamin B6–dependent breakdown of homocysteine, because it is similar in structure to theophylline (1,3-dimethylxanthine), a known vitamin B6 antagonist (20). Chlorogenic acid may raise homocysteine concentrations because of its involvement in O-methylation reactions: the transfer of a methyl group from S-adenosylmethionine to phenolic compounds produces homocysteine (21). Ulvik et al. report an association between high coffee consumption and lower blood concentrations of folate and vitamin B6, with this association being limited to the population with high concentrations of these vitamins (8). These investigators hypothesize that caffeine may stimulate the urinary excretion of folate and vitamin B6 when circulating concentrations are high. In randomized trials of coffee and chlorogenic acid, reductions in concentrations have been found for vitamin B6 (22) and folate (21). Although this mechanism may contribute to the effect of caffeine on homocysteine concentrations, it is unlikely to fully explain this effect because other trials have found that coffee and caffeine substantially increase homocysteine concentrations in the absence of changes in B vitamin concentrations (4)(20).

Given the observational nature of the study by Ulvik et al., potential sources of bias and confounding effects have to be considered in the interpretation of the results. A cross-sectional study design often complicates the interpretation of the direction of effects; however, people are not generally aware of their B vitamin or homocysteine concentrations. Therefore, the effects of these outcome variables on coffee-consumption habits ("reverse causation") are unlikely. Confounding variables are more likely to have affected the results, because high coffee consumption tends to be associated with a less health-conscious lifestyle. Indeed, Ulvik et al. report that study participants with high coffee consumption were 3 times as likely to smoke cigarettes (8). It is plausible that high coffee consumption was also associated with a lower intake of folate and vitamin B6 from foods and vitamin supplements, but the authors were not able to adjust for these potential confounders. Therefore, the intriguing hypothesis raised by Ulvik et al. that high caffeine intake reduces B vitamin status requires confirmation in further studies.

Results from recent studies suggest that coffee consumption may also have beneficial effects on biological risk factors for CHD. Coffee has been identified as a major contributor to the in vitro antioxidant capacity of the diet (23). Consumption of coffee acutely increases the concentrations of phenolic compounds in LDL cholesterol particles and platelets, increases ex vivo resistance to LDL oxidation, and reduces platelet aggregation in healthy volunteers (24)(25). Decaffeinated coffee and phenolic coffee components improved insulin sensitivity in animal studies (26)(27), and habitual coffee consumption has been associated with a substantially lower risk of type 2 diabetes in prospective cohort studies (14). Coffee has also been proposed to possibly have beneficial effects on CHD risk through prevention of postprandial hypotension (6) and inflammation reduction (7). Further research on these potential beneficial effects of coffee is required and could lead to the development of types of coffee with improved health effects.

What can we conclude about the paradox of adverse effects of high coffee consumption on various biological risk factors for CHD and an apparent lack of increase in CHD incidence? First, the prospective cohort studies suggesting that coffee consumption is not associated with an increased risk of CHD have been conducted in populations that predominantly consumed paper-filtered coffee (5)(6)(7). Effects are likely to be different for consumption of types of coffee high in the cholesterol-raising compound cafestol. Second, the detrimental short-term effects of caffeine intake on blood pressure and insulin sensitivity may be reduced by the development of partial tolerance with long-term use and the counteracting effects of other coffee components. In contrast, the effects of coffee on homocysteine appear to remain after long-term coffee consumption, with both caffeine and chlorogenic acid contributing to this effect. It is unclear, however, whether homocysteine has a causal effect on the development of CHD or is merely an innocent bystander (28). Finally, beneficial effects of coffee on biological pathways involved in the development of CHD may compensate for detrimental effects on other biological risk factors. In sum, currently available knowledge on the effects of paper-filtered coffee on biological CHD risk factors is compatible with the observation that coffee consumption is not associated with a higher risk of CHD in prospective cohort studies. General recommendations to reduce coffee consumption as a means to reduce the risk of CHD do not seem warranted, and public health efforts should prioritize other lifestyle factors, including quitting smoking, increasing physical activity and diet quality, and preventing excess caloric intake.


Acknowledgments

Grant/Funding Support: None declared.

Financial Disclosures: None declared.


References

  1. Jee SH, He J, Appel LJ, Whelton PK, Suh I, Klag MJ. Coffee consumption and serum lipids: a meta-analysis of randomized controlled clinical trials. Am J Epidemiol 2001;153:353-362.[Abstract/Free Full Text]
  2. Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens 2005;23:921-928.[Web of Science][Medline] [Order article via Infotrieve]
  3. Keijzers GB, De Galan BE, Tack CJ, Smits P. Caffeine can decrease insulin sensitivity in humans. Diabetes Care 2002;25:364-369.[Abstract/Free Full Text]
  4. Urgert R, van Vliet T, Zock PL, Katan MB. Heavy coffee consumption and plasma homocysteine: a randomized controlled trial in healthy volunteers. Am J Clin Nutr 2000;72:1107-1110.[Abstract/Free Full Text]
  5. Lopez-Garcia E, van Dam RM, Willett WC, Rimm EB, Manson JE, Stampfer MJ, et al. Coffee consumption and coronary heart disease in men and women: a prospective cohort study. Circulation 2006;113:2045-2053.[Abstract/Free Full Text]
  6. Greenberg JA, Dunbar CC, Schnoll R, Kokolis R, Kokolis S, Kassotis J. Caffeinated beverage intake and the risk of heart disease mortality in the elderly: a prospective analysis. Am J Clin Nutr 2007;85:392-398.[Abstract/Free Full Text]
  7. Andersen LF, Jacobs DR, Jr, Carlsen MH, Blomhoff R. Consumption of coffee is associated with reduced risk of death attributed to inflammatory and cardiovascular diseases in the Iowa Women’s Health Study. Am J Clin Nutr 2006;83:1039-1046.[Abstract/Free Full Text]
  8. Ulvik A, Vollset SE, Hoff G, Ueland PM. Coffee consumption and circulating B-vitamins in healthy middle-aged men and women. Clin Chem 2008;54:1489-1496.[Abstract/Free Full Text]
  9. Battram DS, Arthur R, Weekes A, Graham TE. The glucose intolerance induced by caffeinated coffee ingestion is less pronounced than that due to alkaloid caffeine in men. J Nutr 2006;136:1276-1280.[Abstract/Free Full Text]
  10. Robertson D, Wade D, Workman R, Woosley RL, Oates JA. Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest 1981;67:1111-1117.[Web of Science][Medline] [Order article via Infotrieve]
  11. MacKenzie T, Comi R, Sluss P, Keisari R, Manwar S, Kim J, et al. Metabolic and hormonal effects of caffeine: randomized, double-blind, placebo-controlled crossover trial. Metabolism 2007;56:1694-1698.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  12. van Dam RM, Pasman WJ, Verhoef P. Effects of coffee consumption on fasting blood glucose and insulin concentrations: randomized controlled trials in healthy volunteers. Diabetes Care 2004;27:2990-2992.[Free Full Text]
  13. Winkelmayer WC, Stampfer MJ, Willett WC, Curhan GC. Habitual caffeine intake and the risk of hypertension in women. JAMA 2005;294:2330-2335.[Abstract/Free Full Text]
  14. van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 2005;294:97-104.[Abstract/Free Full Text]
  15. Urgert R, van der Weg G, Kosmeijer-Schuil TG, van de Bovenkamp P, Hovenier R, Katan MB. Level of the cholesterol-elevating diterpenes cafestol and kahweol in various coffee brews. J Agric Food Chem 1995;43:2167-2172.[CrossRef][Web of Science]
  16. Graham TE, Hibbert E, Sathasivam P. Metabolic and exercise endurance effects of coffee and caffeine ingestion. J Appl Physiol 1998;85:883-889.[Abstract/Free Full Text]
  17. Suzuki A, Yamamoto N, Jokura H, Yamamoto M, Fujii A, Tokimitsu I, Saito I. Chlorogenic acid attenuates hypertension and improves endothelial function in spontaneously hypertensive rats. J Hypertens 2006;24:1065-1073.[Web of Science][Medline] [Order article via Infotrieve]
  18. de Paulis T, Schmidt DE, Bruchey AK, Kirby MT, McDonald MP, Commers P, et al. Dicinnamoylquinides in roasted coffee inhibit the human adenosine transporter. Eur J Pharmacol 2002;442:215-223.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  19. de Bree A, Verschuren WM, Blom HJ, Kromhout D. Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol 2001;154:150-154.[Abstract/Free Full Text]
  20. Verhoef P, Pasman WJ, Van Vliet T, Urgert R, Katan MB. Contribution of caffeine to the homocysteine-raising effect of coffee: a randomized controlled trial in humans. Am J Clin Nutr 2002;76:1244-1248.[Abstract/Free Full Text]
  21. Olthof MR, Hollman PC, Zock PL, Katan MB. Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans. Am J Clin Nutr 2001;73:532-538.[Abstract/Free Full Text]
  22. Grubben MJ, Boers GH, Blom HJ, et al. Unfiltered coffee increases plasma homocysteine concentrations in healthy volunteers: a randomized trial. Am J Clin Nutr 2000;71:480-484.[Abstract/Free Full Text]
  23. Pulido R, Hernandez-Garcia M, Saura-Calixto F. Contribution of beverages to the intake of lipophilic and hydrophilic antioxidants in the Spanish diet. Eur J Clin Nutr 2003;57:1275-1282.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  24. Natella F, Nardini M, Belelli F, et al. Effect of coffee drinking on platelets: inhibition of aggregation and phenols incorporation. Br J Nutr 2008;:1-7.
  25. Natella F, Nardini M, Belelli F, Scaccini C. Coffee drinking induces incorporation of phenolic acids into LDL and increases the resistance of LDL to ex vivo oxidation in humans. Am J Clin Nutr 2007;86:604-609.[Abstract/Free Full Text]
  26. Shearer J, Farah A, de Paulis T, Bracy DP, Pencek RR, Graham TE, Wasserman DH. Quinides of roasted coffee enhance insulin action in conscious rats. J Nutr 2003;133:3529-3532.[Abstract/Free Full Text]
  27. Shearer J, Sellars EA, Farah A, Graham TE, Wasserman DH. Effects of chronic coffee consumption on glucose kinetics in the conscious rat. Can J Physiol Pharmacol 2007;85:823-830.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  28. Ueland PM, Clarke R. Homocysteine and cardiovascular risk: considering the evidence in the context of study design, folate fortification, and statistical power. Clin Chem 2007;53:807-809.[Free Full Text]



The following articles in journals at HighWire Press have cited this article:


Home page
Diabetes CareHome page
W. Zhang, E. Lopez-Garcia, T. Y. Li, F. B. Hu, and R. M. van Dam
Coffee Consumption and Risk of Cardiovascular Diseases and All-Cause Mortality Among Men With Type 2 Diabetes
Diabetes Care, June 1, 2009; 32(6): 1043 - 1045.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Dam, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Dam, R. M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS